Evidence map›Paper›PMID 41958678›Full record

ArticleFrontiers in immunology2026

Gut microbe

Jia Li, Jie Shen, Dongyan Lu, Enci Ding, Lijuan Wei

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jia LiDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.
Jie ShenDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.
Dongyan LuDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.
Enci DingDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.
Lijuan WeiDepartment of Nuclear Medicine, Tianjin First Central Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence suggests a link between the gut microbiome and papillary thyroid carcinoma (PTC), but the causal relationships and the impact on the tumor immune microenvironment (TME) are poorly understood. This study aimed to elucidate the causal role of specific gut microbes in PTC and uncover the underlying immunological and molecular mechanisms. We employed a multi-stage design, beginning with a two-sample Mendelian randomization (MR) analysis using large-scale GWAS data to infer causality. Findings were then validated in 450 PTC patients from The Cancer Genome Atlas (TCGA) by analyzing correlations between microbial abundance, gene expression, immune cell infiltration, and survival. Finally, the core mechanism was confirmed through extensive

Indexed as

Gastrointestinal MicrobiomeReceptor, trkAThyroid Cancer, PapillaryThyroid NeoplasmsTumor MicroenvironmentCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleUp-RegulationNTRK1 protein, humanReceptor, trkAgut microbiotaimmunosuppressionM2 macrophagesMendelian randomizationmetabolitesNTRK1papillary thyroid carcinomaTerrisporobacter

Identifiers

PMID41958678
PMCPMC13057521

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.